iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/26016444/
Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;160(8):2075-8.
doi: 10.1007/s00705-015-2461-8. Epub 2015 May 29.

Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine

Suvi Lappalainen  1 , Ana Ruth Pastor, Maria Malm, Vanessa López-Guerrero, Fernando Esquivel-Guadarrama, Laura A Palomares, Timo Vesikari, Vesna Blazevic
Affiliations

Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine

Suvi Lappalainen et al. Arch Virol. 2015 Aug.

Abstract

Live oral rotavirus (RV) vaccines are part of routine childhood immunization but are associated with adverse effects, particularly intussusception. We have developed a non-live combined RV - norovirus (NoV) vaccine candidate consisting of human RV inner-capsid rVP6 protein and NoV virus-like particles. To determine the effect of delivery route on induction of VP6-specific protective immunity, BALB/c mice were administered a vaccine containing RV rVP6 intramuscularly, intranasally or a combination of both, and challenged with murine RV. At least 65 % protection against RV shedding was observed regardless of delivery route. The levels of post-challenge serum VP6-specific IgA titers correlated with protection.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pre- and post-challenge VP6-specific IgG (a) and IgA (b) antibodies in sera of individual mice immunized IM and IN with the trivalent vaccine containing rVP6 (5 mice/group) or sequentially IM+IN with rVP6 (4 mice/group). A sample was considered ELISA positive if the optical density at 490 nm (OD490) was above the set cutoff value (mean OD490 of control mice + 3 × SD) and ≥0.1. All control mice were combined (8 mice/group). Endpoint titers of individual mice, expressed as log10 of the reciprocal of the highest sample dilution giving a positive reading, as well as geometric mean titers of the groups (-----) at study weeks 5 (pre-challenge tail-blood sample) and 7 (post-challenge termination sera) are shown. A titer of 50 was assigned for all negative samples, being a half of the starting serum dilution. The statistical differences between non-parametric observations of independent groups were assessed by Mann-Whitney U-test (SPSS Inc, Chicago, IL); p ≤ 0.05 was considered to indicate a statistically significant difference
Fig. 2
Fig. 2
Protection against RV shedding in immunized mice. Viral shedding curves (OD405 versus day post-challenge) for each animal were plotted and the reduction in viral load was calculated by comparing the mean area under the shedding curve of the immunized mice to the mean area under the curve of the controls. a. Viral shedding curves of experimental groups. Each point represents the daily average of antigen shed per group with standard error of the mean. Asterisks (*) indicate a significant difference (p ≤ 0.05; Mann-Whitney U-test) in daily shedding between the immunized and control mice. b. Reductions in virus shedding of VP6-immunized mice following challenge. Mean percent reductions of the experimental groups with standard error of the means are shown. A >50 % reduction in virus shedding was considered significant protection from virus challenge, as reported previously
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yen C, Tate JE, Hyde TB, et al. Rotavirus vaccines: current status and future considerations. Hum Vaccin Immunother. 2014;10:1436–1448. doi: 10.4161/hv.28857. - DOI - PMC - PubMed
    1. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22. doi: 10.1056/NEJMoa052434. - DOI - PubMed
    1. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33. doi: 10.1056/NEJMoa052664. - DOI - PubMed
    1. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376:615–623. doi: 10.1016/S0140-6736(10)60755-6. - DOI - PubMed
    1. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289–298. doi: 10.1056/NEJMoa0904797. - DOI - PubMed

MeSH terms